| 영문 | cell-mediated immunity | 한글 | 세포매개면역 |
|---|---|---|---|
| 설명 | 면역이란 신체를 외부의 물질로부터 보호하는 행위를 말한다. 여기에는 특이적 면역과 비특이적 면역의 두 가지가 있다. 비특이적 면역이라함은 특정한 물질에 관계하는 면역이 아니라 특정 대상이 없이 모든 외부 물체에 작용할 수 있는 면역을 말한다. 여기에는 소변의 흐름, 눈물의 흐름, 피부의 비투과성 등의 기계적인 것도 포함되고 피속에 돌아다니는 세포 중에서 비특이적으로 외부의 물질을 포식하는 세포들(예를 들면 큰포식세포(macrophage)의 활동도 포함이 된다. 세포매개면역이란 특이한 물질을 감지할 수 있는 세포를 생성하게 하여 그것으로 하여금 그 물질을 포식하게 하는 것을 말한다. |
||
| 영문 | nerve cell | 한글 | 신경세포 |
|---|---|---|---|
| 설명 | 신경세포는 올바른 신경전달을 위한 각 부분별로 나뉘어져 있다. 신경세포에서는 전해져오는 자극을 전기적인 신호로 바뀌어 보내거나 받게 된다. 이런 전기적인 현상은 각 신경세포내에 존재하는 각 이온채널(ion channel: ion이란 나트륨, 칼륨 등을 지칭하는 말들로써, 이들이 세포막에 의해 나뉘어질 때 생기는 전압차가 전기적 자극을 일으키고 유지하는데 결정적인 역할을 한다)들의 작용에 의해 이루어지게 된다. |
||
| 영문 | glia cell | 한글 | 아교세포 |
|---|---|---|---|
| 설명 | 신경세포 사이에서 그물구조를 이루며 이를 지지하는 조직. 신경아교세포는 신경모세포와 갈라진 아교모세포가 다시 여러 형태로 분화-성장한 것이다. 뇌실이나 척수중심관의 벽을 덮고 원주상 또는 입방형이며, 초기에는 유리면에 섬모가 있다. 대형세포는 별뇌실막세포는 아교세포라고 하며, 신경세포나 신경섬유 사이에 산재한다. 그 외에 희소돌기아교세포도 포함된다. |
||
| 영문 | reserve cell | 한글 | 예비세포 |
|---|---|---|---|
| 설명 | 일반적으로 상피조직에서 이미 있던 상피세포가 손상을 받아 사멸하면 매꿔지는 그 밑에 있는 미분화세포 예를 들면, 기관지 내표면을 덮는 중층 원주 상피의 기저에 있는 작은 미분화 상피 세포. |
||
| AMA | against medical advice; alkaline membrane assay; American Management Association; American Medical A... |
|---|---|
| NA | Avogadro constant or number; nalidixic acid; Narcotics Anonymous; network administrator; neuraminida... |
| ACC | accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst... |
| ADCC cell | Antibody Dependent Cellular(= Cell-Mediated) Cytotoxicity cell |
| SCA | self-care agency; severe congenital anomaly; sickle-cell anemia; single-camera autostereoscopic [ima... |
| agglutinating antibody | 1. An antibody that causes clumping or agglutination of the bacteria or other cells which either stimulated the formation of the agglutinin, or contain immunologically similar, reactive antigen. Synonym: agglutinating antibody, immune agglutinin. 2. A substance, other than a specific agglutinating antibody, that causes organic particles to agglutinate, commonly qualified, e.g., plant agglutinin. (05 Mar 2000) |
|---|---|
| anaphylactic antibody | Antibody that has an affinity for certain kinds of cells, in addition to and unrelated to its specific affinity for the antigen that induced it, because of the properties of the Fc portion of the heavy chain. See: heterocytotropic antibody, homocytotropic antibody, cytotropic antibody test. Synonym: anaphylactic antibody, cytophilic antibody. (05 Mar 2000) |
| anti-basement membrane antibody | Autoantibodies to renal glomerular basement membrane antigens. (05 Mar 2000) |
| antibody | An immunoglobulin molecule that has a specific amino acid sequence by virtue of which it interacts only with the antigen that induced its synthesis in cells of the lymphoid series (especially plasma cells) or with antigen closely related to it. Antibodies are classified according to their ode of action as agglutinins, bacteriolysins, haemolysins, opsonins, precipitins, etc. (18 Nov 1997) |
| antibody affinity | A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes. (12 Dec 1998) |
| antibody aldolase | <enzyme> Prepared by reactive immuninization to catalyze a wide variety of aldol reactions and decarboxylations Registry number: EC 4.1.2.- Synonym: fab 33f12, aldolase catalytic antibody (26 Jun 1999) |
| antibody-coated bacteria test, urinary | Fluorescent antibody technique for visualizing antibody-bacteria complexes in urine. The presence or absence of antibody-coated bacteria in urine correlates with localization of urinary tract infection in the kidney or bladder, respectively. (12 Dec 1998) |
| antibody combining site | <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope). Also used of the site on a ligand molecule to which a cell surface receptor binds. (18 Nov 1997) |
| antibody deficiency disease | <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms. See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency. Synonym: antibody deficiency disease. (05 Mar 2000) |
| antibody deficiency syndrome | <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms. See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency. Synonym: antibody deficiency disease. (05 Mar 2000) |
| antibody-dependent enhancement | Enhancement of viral infectivity caused by non-neutralizing antibodies. There are at least two mechanisms known to account for this: mediation by fc receptors (receptors, fc) or by complement receptors (receptors, complement). Either the virus is complexed with antiviral IgG and binds to fc receptors, or virus is coated with antiviral IgM and binds to complement receptors. (12 Dec 1998) |
| Antibody Directed Enzyme Prodrug Therapy | <pharmacology> A method for targeting a drug to a specific tissue, in which the targeting agent and the drug are administered separately. The drug is designed to be inactive (a prodrug) until it is converted by an enzyme, which is the targeting agent. The enzyme is coupled to an antibody that directs it to the tissue of interest. When the enzyme arrives at the tissue, the prodrug is activated only at that site, sparing other tissues from potentially toxic side effects. Acronym: ADEPT (14 Nov 1997) |
| antibody diversity | The phenomenon of immense variability characteristic of antibodies, which enables the immune system to react specifically against the essentially unlimited kinds of antigens it encounters. Antibody diversity is accounted for by three main theories: 1) the germ line theory, which holds that each antibody-producing cell has genes coding for all possible antibody specificities, but expresses only the one stimulated by antigen; 2) the somatic mutation theory, which holds that antibody-producing cells contain only a few genes, which produce antibody diversity by mutation; and 3) the gene rearrangement theory, which holds that antibody diversity is generated by the rearrangement of variable region gene segments during the differentiation of the antibody-producing cells. (12 Dec 1998) |
| antibody excess | In a precipitation test, the presence of antibody in an amount greater than that required to combine with all of the antigen present. (05 Mar 2000) |
| antibody induced lysis | <haematology> The term is imprecise and should not be used since there is confusion as to which mechanism is involved, i.e. Natural killing or complement lysis. See: complement lysis, natural killer cells. (09 Feb 1998) |